In-vitro growth inhibition of bacterial pathogens by probiotics and a synbiotic: product composition matters.

In-vitro growth inhibition of bacterial pathogens by probiotics and a synbiotic: product composition matters.

PMID: 

Int J Environ Res Public Health. 2020 May 11 ;17(9). Epub 2020 May 11. PMID: 32403297

Abstract Title: 

In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters.

Abstract: 

A variety of activities potentially contribute to the beneficial effects of probiotic bacteria observed in humans. Among these is a direct inhibition of the growth of pathogenic bacteria in the gut. The present study characterizes head-to-head the in-vitro pathogen growth inhibition of clinically relevant infectious bacterial strains by different types of probiotics and a synbiotic. In-vitro growth inhibition ofandwere determined. Investigated products were a yeast mono strain probiotic containing, bacterial mono strain probiotics containing eitheror, a multi strain probiotic containing three, and a multi strain synbiotic containing nine different probiotic bacterial strains and the prebiotic fructooligosaccharides (FOS). Inhibition of pathogens was moderate byand, medium byand themixture and strong by the multi strain synbiotic. Head-to-head in-vitro pathogen growth inhibition experiments can be used to differentiate products from different categories containing probiotic microorganisms and can support the selection process of products for further clinical evaluation.

read more

13
Like
Save

Comments

Write a comment

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.